Published in Cancer Weekly, May 11th, 2004
NCCN's Colon, Rectal, and Anal Cancer panel met recently to discuss incorporation of two newly approved agents into treatment regimens for advanced colon and rectal cancer and to modify recommendations for adjuvant therapy for node-positive colon cancer.
For first line therapy of advanced colon and rectal cancer, in patients who can tolerate intensive chemotherapy, the panel added recommendations for regimens using bevacizumab (Avastin; Genentech) in combination with 5-FU based regimens including those...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.